title: [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
abstract: In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups). Response to the treatment was 32.7% in those receiving carmustin +5-fluorouracil, 26.3% in those on carmustin + ftorafur. This difference occurred among the 42 patients with gastric adenocarcinoma (33.3% compared with 25%), as well as in 11 with pancreatic adenocarcinoma, and in 56 with colorectal adenocarcinoma (32.1% and 28.6%). Median survival time for 5-fluorouracil + carmustin was 330 days, double that for ftorafur + carmustin (163 days). Bone-marrow toxicity (leukopenia, thrombopenia) was below 10% for both drug combinations. Alopecia occurred in only a few patients. Gastro-intestinal toxicity was common (20% and 18.5%, respectively), but there was no difference between the two groups. The somewhat lower effectiveness of ftorafur compared with 5-fluorouracil was probably due to the deliberately smaller dosage of the former.
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use*; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D011379:Prognosis; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D005641:Tegafur; D005472:Fluorouracil; D002330:Carmustine
vernacular_title: Prospektive kontrollierte Studie bei metastasierten gastrointestinalen Tumoren. Vergleich zwischen 5-Fluorouracil-Carmustin un Ftorafur-Carmustin.